Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label safety study of HS-10506 in Chinese adults with insomnia disorder
CTR20262272Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HS-10506 in Insomnia, sponsored by Hengrui Therapeutics. Started Jul 2026; status: active.
02
Drugs
HS-10506
03
Conditions
Insomnia
Beyond the preview
Go deeper on CTR20262272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262272.